Tagged with Association,

Canada Imran Ali, senior manager of the pan-Canadian Pharmaceutical Alliance (pCPA) Office, the body that provides dedicated centralized support to the national negotiating process for drug prices, representing all 14 public drug plan jurisdictions in Canada, discusses the mandate of the pCPA, the main achievements so far, as well as the…

UK Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits of inter-stakeholder collaboration. Entering 2018, three key themes affecting the British generics industry are Brexit, a new life science industry…

Baltics SIFFA’s Valters Bolēvics discusses Latvia’s competitiveness in embracing medical innovations, current healthcare reforms, and the country’s enduring potential as a pharmaceutical investment destination. The Association of International Research-based Pharmaceutical Manufacturers (SIFFA) was initially founded in 1996 to act as a united voice for five multinationals that had penetrated the local…

Baltics Janis Silins of the Association of Biopharmaceutical Drug Manufacturers in Latvia discusses the organization’s purpose, collaboration efforts, and role in shaping policy reform. Could you please start by introducing the Association of Biopharmaceutical Drug Manufacturers in Latvia (Biofarmaceitisko Ražotāju Asociācijas Latvijā (BRAL)) and your role within the association? “We strive…

Ecuador Roberto Aspiazu, executive director of the Ecuadorian Business Committee and honorary president of the Mexican Chamber of Commerce in Ecuador, comments on the country’s economic outlook and international trade relations with Mexico, the urgent need for Ecuador to shift its growth paradigm towards increased private investment and explains how the…

Serbia Ana Grujovic, executive director of the Swiss-Serbian Chamber of Commerce (SSCC) who has been overseeing Swiss-Serbian business relations since 2014, explains the successful progression of the Chamber since its establishment, the traits that characterize the Serbian market, and the positive indicators for investors looking to explore operations along the Danube.…

Serbia Ana Popovic, general manager of Serbia’s generics association, Genezis, gives her thoughts on how the generics industry has progressed in the country, what room for improvement remains, and the impact of EU succession. Where does Genezis stand in 2017 and what is keeping you busy at the moment? “The Serbian…

Brazil Paulo Henrique Fraccaro, superintendent of the Brazilian Medical and Dental Devices Manufacturers Association (ABIMO), describes the central role of the association within the Brazilian medtech industry, the phenomenal potential of Brazil’s medtech sector for companies choosing to establish a production facility in Brazil and the importance of increased efficiency and…

Lithuania Leonas Kalėtinas, executive director at the Lithuanian Innovative Pharmaceutical Industry Association (IFPA), explains the main dynamics impacting the innovative pharmaceutical industry in the country as well as some initiatives developed in collaboration with the national government to continue driving the Lithuanian pharmaceutical sector moving forward. In 2014, the industry signed…

Poland Piotr Ponikowski, president of the Polish Cardiac Society, discusses the positive steps Poland is taking to construct an effective program against cardiovascular disease as well as the importance of a structured national prevention strategy. Furthermore, he highlights the importance of the Society acting as a partner with the entire value…

Lithuania Šarūnas Narbutas, president at the Lithuanian Cancer Patients’ Coalition (POLA), explains the role of patients in shaping the Lithuanian healthcare system as well as the importance of having an integral approach when discussing with healthcare stakeholders to drive progress in the country. You hold a number of roles in different…

Serbia Martin Knapp, managing director of the German Chamber of Commerce in Serbia, highlights how Serbia can further develop a more investment-friendly environment and the progress that the country has already made in this regard. Mr. Knapp, it is your second tenure as the Director of AHK in Serbia. What makes…